Syncom Formulations (India) Limited — Important, 05-03-2025: Updates

SYNCOM Formulations has announced a board meeting on February 10, 2025, resulting in the approval of its standalone and consolidated financial results for the quarter and nine months ended December 31, 2024.

**Financial Highlights:** For the quarter, revenue from operations rose to ₹12702.92 cr, up from ₹6334.22 cr a year ago, contributing to total income of ₹13085.41 cr. Profit before tax was reported at ₹1690.48 cr, translating to an EPS of ₹0.14. For the nine months, revenue reached ₹31438.60 cr, with a profit of ₹4165.05 cr.

**Strategic Initiatives and Growth Drivers:** The company continues to focus on its pharmaceutical segment, which significantly contributed to revenue, reflecting robust demand for its products.

**Business Developments:** No new partnerships or acquisitions were disclosed; however, the steady revenue growth indicates a strong operational framework.

**Market Position and Competitive Advantage:** SYNCOM maintains a solid position in the pharmaceuticals market, buoyed by its diversity in trading and property rental segments, contributing to its overall revenue stability.

**Investor Implications:** Strong revenue growth and profitability metrics present a positive outlook for investors, who may see continued potential growth as SYNCOM navigates market dynamics effectively.